©NIJPP
Publications 2026

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY (NIJPP)

Volume 7 Issue 1 Page 87-94, 2026

https://doi.org/10.59298/NIJPP/2026/718794

Nanomedicine-Based Strategies to Target Chronic Inflammation in Obesity-Driven Type 2 Diabetes

Bwanbale Geoffrey David

Faculty of Pharmacy Kampala International University Uganda

ABSTRACT

Obesity-driven type 2 diabetes (T2D) is sustained by chronic, low-grade inflammation that disrupts insulin signaling across adipose tissue, liver, skeletal muscle, and vascular beds. Hypertrophic adipocytes and stromal immune cells form an inflammatory niche characterized by cytokine secretion, lipotoxic stress, hypoxia, and extracellular matrix remodeling. Conventional anti-inflammatory agents can improve insulin sensitivity but are limited by off-target toxicities, short half-lives, and inadequate delivery to diseased depots. Nanomedicine offers a precision toolkit to overcome these barriers by concentrating therapeutics in inflamed tissues, enabling intracellular delivery to key immune populations, coordinating controlled and stimuli-responsive release, and coupling therapy with imaging for on-treatment monitoring. This review synthesizes mechanistic underpinnings of metabolic inflammation; design principles for adipose- and liver-homing nanoparticles; small-molecule, biologic, and nucleic acid payloads that reprogram innate and adaptive immune tone; and theranostic approaches for quantifying target engagement. We discuss safety, manufacturability, and regulatory considerations unique to chronic metabolic indications and propose clinical trial frameworks that integrate continuous glucose monitoring with inflammatory biomarkers and organ-level imaging. By aligning materials science with immunometabolic biology, nanomedicine can convert broad immunosuppression into tissue- and pathway-selective modulation, improving insulin sensitivity while minimizing systemic risk.

Keywords: metabolic inflammation; nanomedicine; adipose tissue; macrophages; cytokines; insulin resistance; lipid nanoparticles; nucleic acid therapeutics; theranostics; type 2 diabetes

INTRODUCTION

Type 2 diabetes that emerges on the background of obesity reflects a convergence of metabolic overload and persistent, low-grade inflammation[1–4]. As adipocytes expand, local hypoxia, mechanical stress, and lipotoxic intermediates trigger stress pathways that impair insulin signaling. Adipose tissue macrophages accumulate and shift toward proinflammatory states; T cells, B cells, dendritic cells, and innate lymphoid cells further sculpt a niche that elevates cytokines such as TNF, IL-6, and IL-1β[5–7]. These signals alter insulin receptor substrate phosphorylation, suppress glucose transport, and propagate hepatic gluconeogenesis and skeletal muscle insulin resistance[8, 9]. Systemically, circulating lipoproteins, free fatty acids, and microbial products from an altered gut barrier feed into pattern recognition receptor activation in metabolic organs. The result is a distributed pathology in which inflammation and metabolism are inseparable.

Therapeutic advances in incretin pharmacology and sodium–glucose cotransport blockade have transformed glycemic outcomes and cardiometabolic risk, yet they were not designed primarily to resolve the inflammatory microenvironments that entrench insulin resistance[10–12]. Broad anti-inflammatory agents can improve glycemia in select contexts, but they often expose patients to infection risk or organ toxicity and rarely localize to the adipose or hepatic niches where they would be most beneficial. Moreover, inflammatory signaling is highly compartmentalized. The profile of cytokines, lipid mediators, and immune cell subsets differs between visceral and subcutaneous adipose tissue, within the liver's lobular zones, and across vascular territories. A precision strategy must therefore account for tissue specificity and cell-type diversity while respecting the chronic nature of the disease[13].

Nanomedicine provides the necessary levers. Nanoparticles can be constructed from lipids, biodegradable polymers, proteins, or hybrid materials to encapsulate small molecules, peptides, monoclonal antibodies, or nucleic acids[14–17]. They protect labile cargo from degradation, extend circulation time, and exploit the

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X
distinct vascular and extracellular matrix features of inflamed tissues to enhance retention. Surface ligands direct particles to cell populations central to metabolic inflammation like macrophages, endothelial cells, adipocytes, and hepatic stellate cells while stimuli-responsive linkers synchronize release with local cues such as pH, redox state, enzyme activity, or reactive oxygen species.[18–21] For nucleic acid therapeutics, nanoparticles are essential for cellular entry and endosomal escape, enabling silencing or editing of genes that govern inflammasome activity, cytokine production, and lipid handling. Importantly, nanocarriers can be engineered for subcutaneous, intraperitoneal, or oral routes, each offering different biodistribution profiles that may be matched to pathology[17, 19, 22, 23].

Quantification is as important as delivery. Imaging labels embedded within nanoparticles create theranostic platforms that visualize target engagement and residence time, allowing dose optimization and patient stratification[24]. Noninvasive biomarkers, like circulating cytokines, lipoprotein-associated mediators, and exosomal signatures provide orthogonal readouts and can be integrated with continuous glucose monitoring to link anti-inflammatory activity to metabolic outcomes. In this way, nanomedicine reframes immunomodulation as a measured intervention rather than a blind systemic push[25, 26].

Translation, however, imposes constraints. Chronic metabolic disease requires long-term safety, predictable manufacturing, and usability that fits daily life. Immunogenicity against carrier materials, complement activation, and reticuloendothelial accumulation must be minimized[27]. Manufacturing must deliver tight control of particle attributes and release kinetics under GMP, with stability in real-world conditions. Clinical trials need endpoints that capture both inflammation resolution and metabolic improvement, demonstrating that localized immunomodulation translates into better glycemic control, reduced insulin requirements, and improved organ health without increasing infection or cardiovascular risk[27].

This review examines how nanotechnology can target chronic inflammation at the heart of obesity-driven T2D. We begin by mapping the immunometabolic landscape and defining actionable targets. We then cover design rules for particles that home to inflamed adipose and liver, follow with payload strategies spanning small molecules, biologics, and nucleic acids, and describe imaging and biomarkers that quantify engagement. Finally, we outline safety, regulatory, and clinical trial pathways to bring these approaches from bench to bedside. The central thesis is that nanomedicine can align the location, timing, and intensity of anti-inflammatory therapy with the distributed, dynamic nature of metabolic disease.

2. Immunometabolic Landscape and Actionable Targets in Obesity-Driven T2D

Chronic inflammation in obesity-driven T2D reflects a network spanning adipose depots, liver, skeletal muscle, pancreatic islets, and vascular beds[28, 29]. In visceral adipose tissue, hypertrophic adipocytes release saturated fatty acids and danger-associated molecular patterns that engage TLR4 and NLRP3 inflammasomes in resident and recruited macrophages[28]. These macrophages, often aggregated into crown-like structures around necrotic adipocytes, produce IL-1β, TNF, and chemokines that sustain leukocyte recruitment and disrupt insulin signaling in neighboring adipocytes[30]. Endothelial cells contribute by expressing adhesion molecules and secreting pro-thromboinflammatory mediators, while fibroblasts remodel the extracellular matrix, stiffening the tissue and impairing capillary function. In the liver, Kupffer cells and infiltrating monocytes sense lipotoxicity and microbial products, amplifying inflammation that drives steatosis progression and hepatic insulin resistance[30]. Skeletal muscle exhibits microvascular rarefaction and altered perfusion responses to insulin, limiting glucose disposal and reinforcing systemic hyperglycemia.

The molecular circuitry presents multiple intervention points. Blocking upstream danger signaling via TLRs or scavenging extracellular vesicle–borne lipids can reduce macrophage priming. Inhibiting NLRP3 activation or IL-1 signaling attenuates cytokine cascades that impair insulin action[31]. Modulating eicosanoid synthesis and specialized pro-resolving mediator pathways can shift the inflammatory response from persistent activation toward resolution. Rewiring macrophage metabolism from glycolysis-dominant to oxidative supports a tissue-repair phenotype that fosters insulin sensitivity[31]. At the endothelial interface, reducing oxidative stress and restoring nitric oxide bioavailability improves perfusion and glucose uptake in muscle and adipose tissue. Addressing fibrosis by tempering TGF-β signaling and matrix cross-linking can normalize tissue mechanics and immune cell trafficking[32].

Targeting requires precision because these pathways are not uniformly pathogenic across organs or disease stages. Adipose tissue inflammation may dominate in some individuals, while hepatic drivers prevail in others. Moreover, immune cells execute beneficial functions in lipid clearance and tissue remodeling; indiscriminate suppression risks impairing homeostasis[33]. Nanomedicine can reconcile these constraints by preferentially delivering modulators to tissues and cell types where they are most needed, achieving effective local concentrations with lower systemic exposure[34, 35]. In particular, macrophages' avid endocytic activity, the altered vasculature of inflamed depots, and matrix changes that trap nanoparticles provide natural handles for selective accumulation. By aligning payloads with the spatial and temporal dynamics of immunometabolic pathology, nanocarriers can turn diffuse anti-inflammatory concepts into practical, organ-tuned interventions.

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

3. Design Principles for Adipose- and Liver-Homing Nanocarriers

Engineering nanoparticles to reach inflamed adipose and liver begins with size, surface chemistry, and stiffness. Particles in the 50–150 nm range generally balance circulation with extravasation through inflamed microvasculature, while softer, deformable constructs can navigate dense extracellular matrix more effectively[36]. Surface coronas that resist opsonization, using zwitterionic or polysarcosine coatings, prolong circulation and reduce premature clearance. For active targeting, ligands that bind adipose endothelium or macrophage receptors such as peptides recognizing prohibitin, scavenger receptors, or integrins, bias deposition in inflamed depots. In the liver, N-acetylgalactosamine and related motifs engage the asialoglycoprotein receptor on hepatocytes, while mannose or scavenger receptor ligands direct particles to Kupffer cells to temper inflammatory signaling at its source[37, 38].

Stimuli-responsive features add temporal control. Acid-labile linkers exploit the mildly acidic milieu of inflamed adipose; ROS- and enzyme-cleavable bonds leverage oxidative and proteolytic activity to trigger release. Ionizable lipids and helper surfactants enhance endosomal escape for nucleic acid payloads, while more inert matrices suit extracellular cytokine blockade. For depot-level persistence, semi-crystalline lipid cores or biodegradable polymer matrices provide sustained release without sharp peaks that might produce systemic immunosuppression [18, 39]. Route of administration further shapes biodistribution. Subcutaneous injection over visceral regions can favor lymphatic drainage to regional depots; intraperitoneal administration accesses hepatic and omental territories; and oral formulations with lymphotropic composition can engage gut–liver immunometabolic loops[40].

Manufacturability and analytics must be integrated from the outset. Scalable microfluidic mixing and controlled nanoprecipitation produce narrow polydispersity and reproducible encapsulation, while stability programs assess particle integrity under refrigerated and stress conditions[41]. Critical quality attributes include size distribution, zeta potential, endotoxin, residual solvent, ligand density, and in vitro–in vivo correlation of release profiles. For chronic use, batch-to-batch consistency in responsiveness to pH, ROS, or enzymes prevents drift in clinical performance[41]. Finally, usability considerations such as viscosity for pen injection, compatibility with common devices, and minimal injection-site reactions determine real-world adoption. Thoughtful design that harmonizes targeting, triggerability, and manufacturability yields carriers capable of delivering precise anti-inflammatory action where insulin signaling needs restoration most.

4. Small-Molecule and Biologic Payloads to Reprogram Inflammatory Niches

Nanocarriers expand the therapeutic index of anti-inflammatory agents by concentrating them in diseased tissues and smoothing pharmacokinetics. For small molecules, encapsulating inhibitors of NLRP3, JAK/STAT, or NF-κB pathways can attenuate cytokine production from macrophages and adipocytes, improving insulin sensitivity with reduced systemic immunosuppression[42]. Delivering AMPK activators and PPAR modulators directly into adipose depots promotes lipid handling and mitochondrial function while dampening inflammatory tone. Specialized pro-resolving mediators, resolvins, protectins, and maresins are potent but chemically fragile; nanoparticle formulation stabilizes them, enabling sustained local pro-resolution cues that facilitate efferocytosis and tissue repair without blunt suppression[42].

Biologics benefit similarly. Monoclonal antibodies or receptor antagonists against IL-1β, IL-6, or TNF can be packaged in long-circulating or depot-homing carriers to minimize systemic exposure and infection risk[43]. Decoy receptors and fusion proteins that sequester chemokines locally can reduce immune cell recruitment into adipose tissue, while growth factor fragments delivered at low, controlled doses promote vascular normalization and resolve hypoxia that sustains inflammation. Enzymatic payloads, such as catalase or superoxide dismutase mimetics, detoxify reactive oxygen species in situ, alleviating endothelial dysfunction and restoring nitric oxide bioavailability for better insulin-mediated perfusion[43].

Combination therapy within a single carrier addresses the multifactorial nature of metabolic inflammation. Co-encapsulation of an NLRP3 inhibitor with a specialized pro-resolving mediator can simultaneously reduce inflammatory initiation and accelerate resolution. Pairing a macrophage-reprogramming agent with an endothelial nitric oxide synthase cofactor restores crosstalk between immune and vascular compartments[44]. Release can be staggered using orthogonal linkers, delivering an initial anti-inflammatory pulse followed by a slower pro-resolving phase. Crucially, local delivery allows lower total doses, reducing risks associated with systemic blockade of immune pathways central to host defense[44].

Translation requires rigorous pharmacology. Depot drug levels, cytokine gradients, and functional outcomes like glucose uptake, hepatic glucose production, and microvascular perfusion should be measured concurrently to map exposure to effect[44]. Safety monitoring must include infection rates, vaccination responses, and laboratory indices to detect unintended immunosuppression, with designs that favor tissue-selective exposure to mitigate these risks. With these elements aligned, nanocarrier-enabled small-molecule and biologic payloads can reprogram inflammatory niches in ways unattainable with conventional formulations.

5. Nucleic Acid Therapeutics to Modulate Immune and Metabolic Gene Networks

Nucleic acid therapeutics offer programmable control over inflammatory and metabolic pathways central to insulin resistance. Small interfering RNAs and antisense oligonucleotides can silence transcripts encoding

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X
inflammasome components, cytokines, or signaling adaptors in macrophages and adipocytes[45]. For example, targeting NLRP3, caspase-1, or IL1B reduces IL-1β maturation and release, while silencing TLR adaptors or chemokine receptors diminishes inflammatory recruitment. Conversely, mRNA delivery can transiently express transcriptional regulators that favor tissue repair and oxidative metabolism, nudging macrophages toward pro-resolving phenotypes and enhancing adipocyte mitochondrial function[45]. Base editors and CRISPR interference expand the palette, enabling durable downregulation of pathogenic regulators, though permanency raises additional safety considerations.

Delivery is the decisive challenge. Lipid nanoparticles with ionizable lipids facilitate endosomal escape, while ligand display biases uptake to macrophages or endothelial cells in inflamed depots[46–48]. Chemical modifications to nucleic acids such as 2′-O-methyl, phosphorothioates, and conjugated sugars, improve stability and reduce innate immune activation, though sequence design must also avoid toll-like receptor motifs. For depot specificity, particles can be administered subcutaneously over target regions or engineered to respond to local oxidative or enzymatic cues that accelerate release only within inflamed tissue. Re-dosing schedules should consider adaptive immune responses to carrier materials and the potential for anti-PEG antibodies; alternative stealth coatings can mitigate these issues[46].

Functional endpoints must validate that gene modulation translates into metabolic gain. Beyond changes in cytokines, assays should quantify improvements in insulin signaling cascades, glucose uptake in muscle and adipose tissue, hepatic glucose output, and microvascular perfusion during hyperinsulinemic states[25, 49, 50]. Single-cell transcriptomics and spatial profiling from optional biopsies can confirm on-target editing or silencing within intended cell populations, while circulating exosomal RNA provides a less invasive window into target engagement.

Safety is paramount for genetic modulation in a chronic disease. Off-target effects, unintended edits, and immune activation require systematic screening and long-term surveillance. For early clinical translation, transient modalities, such as siRNA, ASO, and mRNA, may be preferable to permanent editing, balancing efficacy with reversibility[3, 51]. With careful design, nucleic acid nanotherapeutics can reshape immune and metabolic gene networks in a tissue-selective, titratable manner, offering a powerful complement to pharmacologic anti-inflammatory strategies.

6. Imaging, Biomarkers, and Theranostics for Quantifying Anti-inflammatory Impact

Demonstrating that localized immunomodulation improves metabolic control demands quantitative tools that span molecules, cells, tissues, and whole-body physiology[52]. Theranostic nanoparticles embed imaging reporters, positron emission tomography isotopes, magnetic resonance contrast, photoacoustic dyes, alongside therapeutic cargos to visualize biodistribution, depot uptake, and release in vivo[53]. In adipose tissue, imaging can quantify reductions in inflammatory activity, vascular normalization, and shifts toward oxidative metabolism, while in the liver it can track steatosis resolution and microvascular changes. Photoacoustic or near-infrared readouts suit superficial depots and can be repeated frequently without radiation, whereas PET and MRI provide quantitative, organ-spanning maps for less frequent but decisive assessments.

Circulating biomarkers complement imaging. Panels that include IL-6, IL-1β, TNF, high-sensitivity C-reactive protein, and adipokines reflect systemic inflammatory tone, while lipoprotein-associated phospholipase activity and oxylipin profiles capture lipid mediator balance. Exosomal microRNAs derived from adipose or hepatic cells offer tissue-biased signals of pathway modulation[53]. Functional tests like indirect calorimetry, microvascular reactivity measurements, and standardized meal challenges connect immunologic changes to insulin action and energy handling. Continuous glucose monitoring provides high-resolution glycemic outcomes, including time in range, time below range, and variability, that can be linked temporally to imaging and biomarker shifts during dose finding.

Theranostic logic should be embedded in study design. Baseline imaging can stratify patients by dominant inflammatory geography like visceral adipose, subcutaneous depots, or liver guiding route and dose[54, 55]. On-treatment scans confirm target engagement; predefined thresholds for uptake reduction or perfusion improvement trigger dose escalation, maintenance, or switching. When particles incorporate release-sensing chemistries, fluorescence unquenching upon linker cleavage, clinicians gain a direct window into pharmacodynamics rather than inferring from proxies. Over time, integrating these data with digital phenotypes, activity metrics, and ambient temperature helps account for confounders that influence adipose and vascular behavior.

Translation benefits from standardization. Harmonized imaging protocols, validated biomarker assays, and cross-platform calibration ensure that signals reflect biology rather than instrumentation[56, 57]. Data pipelines that fuse imaging with CGM and laboratory values enable patient-level decision support and accelerate learning across trials. With such infrastructure, theranostics shift anti-inflammatory nanomedicine from promising biology to actionable, monitored care.

7. Safety, Manufacturability, and Clinical Trial Pathways for Chronic Use (≈450 words)

Chronic metabolic indications require nanomedicines that are not only effective but also safe and practical over years. Materials must minimize complement activation and pseudoallergy, avoid persistent organ accumulation,

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X
and exhibit predictable clearance of degraded components[58]. Alternative stealth chemistries reduce the risk of anti-PEG antibodies and maintain pharmacokinetics with repeat dosing. For nucleic acid carriers, innate immune activation should be mitigated through sequence design, high-purity manufacture, and endotoxin control. Local tolerability at injection sites and compatibility with devices commonly used by people with diabetes are essential for adherence[58].

Manufacturing under GMP must deliver tight specifications on particle size, polydispersity, ligand density, and release kinetics, with stability programs that cover cold-chain excursions and real-world handling. Analytical methods should be stability-indicating for both carrier and payload, detecting oxidation, hydrolysis, and aggregation. For theranostic platforms, coordination between drug and imaging chemistry manufacturing is required, including radionuclide handling or contrast agent quality contro[59]l. Environmental and occupational safety plans should address solvent use and nanoparticulate exposure during production.

Clinical trials should pair mechanistic and patient-centered endpoints. Phase 1 studies emphasize safety, biodistribution, and pharmacodynamics, using imaging and biomarker panels alongside continuous glucose monitoring and standardized meal tests[60]. Phase 2 trials adopt adaptive designs where imaging-guided thresholds determine dose and schedule, stratified by visceral adiposity, hepatic fat, and inflammatory biomarker profiles[61]. Co-primary outcomes can combine improvement in time in range or HOMA-IR with predefined reductions in inflammatory imaging signals, demonstrating that tissue-level immunomodulation translates to better glycemic control. Safety monitoring should include infection rates, vaccine responsiveness, and hematologic panels to detect inadvertent immune suppression.

Positioning within care pathways requires comparative effectiveness. To justify adoption, nanomedicine-based anti-inflammatory strategies should show additive benefit to current standards such as GLP-1/GIP receptor agonists and SGLT2 inhibitors, ideally allowing dose reduction of systemic agents that cause adverse effects. Health-economic analyses must consider manufacturing costs against potential reductions in complications, medication burden, and clinic visits. If these elements align with robust safety, manufacturability, measurable target engagement, and meaningful metabolic benefit, nanomedicine can become a durable component of comprehensive T2D care focused on resolving the inflammatory roots of insulin resistance.

CONCLUSIONS

Chronic, low-grade inflammation anchors insulin resistance across adipose tissue, liver, muscle, and the vasculature in obesity-driven type 2 diabetes. Nanomedicine offers a means to address this distributed pathology with precision by delivering anti-inflammatory and pro-resolving agents directly to diseased niches, enabling intracellular access to key immune cells, and synchronizing release with local cues. Nucleic acid therapeutics expand the repertoire by reprogramming gene networks that maintain maladaptive immune states, while theranostic designs quantify target engagement and guide adaptive dosing. Success depends on materials and manufacturing that support long-term safety, on standardized imaging and biomarkers that tie tissue changes to glycemic outcomes, and on clinical trials that prove additive benefit alongside contemporary metabolic drugs. With these pieces in place, nanomedicine-based strategies can transform management of obesity-driven T2D from broad systemic suppression to targeted, measurable, and durable resolution of inflammation, improving insulin sensitivity and everyday life for people living with the disease.

REFERENCES

1. Arnesen, E.K., Thorisdottir, B., Bärebring, L., Söderlund, F., Nwaru, B.I., Spielau, U., Dierkes, J., Ramel, A., Lamberg-Allardt, C., Åkesson, A.: Nuts and seeds consumption and risk of cardiovascular disease, type 2 diabetes and their risk factors: a systematic review and meta-analysis. Food Nutr. Res. 67, 10.29219/fnr.v67.8961 (2023). https://doi.org/10.29219/fnr.v67.8961
2. Baliou, S., Apetroaei, M.-M., Hatzidaki, E., Kuzmin, S.V., Tzatzarakis, M.N., Arsene, A.L., Tsatsakis, A., Ioannou, P.: The Interplay Between Obesity and Type 2 Diabetes: Common Pathophysiological Mechanisms Contributing to Telomere Shortening. Life. 15, 873 (2025). https://doi.org/10.3390/life15060873
3. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
4. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M., Uti, D.E.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
5. Abdillah, A.M., Yun, J.W.: Capsaicin induces ATP-dependent thermogenesis via the activation of TRPV1/β3-AR/α1-AR in 3T3-L1 adipocytes and mouse model. Arch. Biochem. Biophys. 755, 109975 (2024). https://doi.org/10.1016/j.abb.2024.109975
6. Fan, L., Xu, H., Yang, R., Zang, Y., Chen, J., Qin, H.: Combination of Capsaicin and Capsiate Induces Browning in 3T3-L1 White Adipocytes via Activation of the Peroxisome Proliferator-Activated Receptor γ/β3-Adrenergic Receptor Signaling Pathways. J. Agric. Food Chem. 67, 6232–6240 (2019). https://doi.org/10.1021/acs.jafc.9b02191

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

7. Alum, E.U.: Metabolic memory in obesity: Can early-life interventions reverse lifelong risks? Obes. Med. 55, 100610 (2025). https://doi.org/10.1016/j.obmed.2025.100610
8. Schirinzi, V., Poli, C., Berteotti, C., Leone, A.: Browning of Adipocytes: A Potential Therapeutic Approach to Obesity. Nutrients. 15, 2229 (2023). https://doi.org/10.3390/nu15092229
9. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
10. Chhabria, S., Mathur, S., Vadakan, S., Sahoo, D.K., Mishra, P., Paital, B.: A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity. Front. Endocrinol. 13, 1027237 (2022). https://doi.org/10.3389/fendo.2022.1027237
11. Deacon, C.F., Ahrén, B.: Physiology of Incretins in Health and Disease. Rev. Diabet. Stud. RDS. 8, 293–306 (2011). https://doi.org/10.1900/RDS.2011.8.293
12. Holst, J.J., Gasbjerg, L.S., Rosenkilde, M.M.: The Role of Incretins on Insulin Function and Glucose Homeostasis. Endocrinology. 162, bqab065 (2021). https://doi.org/10.1210/endocr/bqab065
13. Rakotoarivelo, V., Lacraz, G., Mayhue, M., Brown, C., Rottembourg, D., Fradette, J., Ilangumaran, S., Menendez, A., Langlois, M.-F., Ramanathan, S.: Inflammatory Cytokine Profiles in Visceral and Subcutaneous Adipose Tissues of Obese Patients Undergoing Bariatric Surgery Reveal Lack of Correlation With Obesity or Diabetes. EBioMedicine. 30, 237–247 (2018). https://doi.org/10.1016/j.ebiom.2018.03.004
14. 4dm1n_diversatechnologies: Overcoming regulatory hurdles in clinical translation of nanomedicine, https://www.diversatechnologies.com/overcoming-regulatory-hurdles-in-clinical-translation-of-nanomedicine/, (2025)
15. Agrahari, V., and Hiremath, P.: Challenges Associated and Approaches for Successful Translation of Nanomedicines Into Commercial Products. Nanomed. 12, 819–823 (2017). https://doi.org/10.2217/nnm-2017-0039
16. Uti, D.E., Omang, W.A., Alum, E.U., Ugwu, O.P.-C., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
17. Alum, E.U., Nwuruku, O.A., Ugwu, O.P.-C., Uti, D.E., Alum, B.N., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
18. Ashrafizadeh, M., Delfi, M., Zarrabi, A., Bigham, A., Sharifi, E., Rabiee, N., Paiva-Santos, A.C., Kumar, A.P., Tan, S.C., Hushmandi, K., Ren, J., Zare, E.N., Makvandi, P.: Stimuli-responsive liposomal nanoformulations in cancer therapy: Pre-clinical & clinical approaches. J. Controlled Release. 351, 50–80 (2022). https://doi.org/10.1016/j.jconrel.2022.08.001
19. Das, S.S., Bharadwaj, P., Bilal, M., Barani, M., Rahdar, A., Taboada, P., Bungau, S., Kyzas, G.Z.: Stimuli-Responsive Polymeric Nanocarriers for Drug Delivery, Imaging, and Theragnosis. Polymers. 12, 1397 (2020). https://doi.org/10.3390/polym12061397
20. Hou, J., Xue, Z., Chen, Y., Li, J., Yue, X., Zhang, Y., Gao, J., Hao, Y., Shen, J.: Development of Stimuli-Responsive Polymeric Nanomedicines in Hypoxic Tumors and Their Therapeutic Promise in Oral Cancer. Polymers. 17, 1010 (2025). https://doi.org/10.3390/polym17081010
21. Lee, H., Rho, W.-Y., Kim, Y.-H., Chang, H., Jun, B.-H.: CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations. Molecules. 30, 542 (2025). https://doi.org/10.3390/molecules30030542
22. Abbasi, H., Kouchak, M., Mirveis, Z., Hajipour, F., Khodarahmi, M., Rahbar, N., Handali, S.: What We Need to Know about Liposomes as Drug Nanocarriers: An Updated Review. Adv. Pharm. Bull. 13, 7–23 (2023). https://doi.org/10.34172/apb.2023.009
23. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
24. Yasir, M., Mishra, R., Tripathi, A.S., Maurya, R.K., shahi, A., Zaki, M.E.A., Al Hussain, S.A., Masand, V.H.: Theranostics: a multifaceted approach utilizing nano-biomaterials. Discov. Nano. 19, 35 (2024). https://doi.org/10.1186/s11671-024-03979-w
25. Zhou, X., Zheng, W., Kong, W., Zeng, T.: Identification of circulating inflammation cytokines as a mediator of gut microbiota and type 2 diabetes mellitus: a Mendelian randomization study. Diabetol. Metab. Syndr. 17, 249 (2025). https://doi.org/10.1186/s13098-025-01792-8
26. Shim, J., Muraru, S., Dobrota, R., Fleisch, E., Distler, O., Barata, F.: Noninvasive, Multimodal Inflammatory Biomarker Discovery for Systemic Inflammation (NOVA Study): Protocol for a Cross-Sectional Study. JMIR Res. Protoc. 13, e62877 (2024). https://doi.org/10.2196/62877

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

27. Harris, C.T., Cohen, S.: Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies. Biodrugs. 38, 205–226 (2024). https://doi.org/10.1007/s40259-023-00641-2
28. Rohm, T.V., Meier, D.T., Olefsky, J.M., Donath, M.Y.: Inflammation in Obesity, Diabetes and related Disorders. Immunity. 55, 31–55 (2022). https://doi.org/10.1016/j.immuni.2021.12.013
29. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov. Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
30. Li, B., Sun, S., Li, J.-J., Yuan, J.-P., Sun, S.-R., Wu, Q.: Adipose tissue macrophages: implications for obesity-associated cancer. Mil. Med. Res. 10, 1 (2023). https://doi.org/10.1186/s40779-022-00437-5
31. Swanson, K.V., Deng, M., Ting, J.P.-Y.: The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477–489 (2019). https://doi.org/10.1038/s41577-019-0165-0
32. Alonaizan, R.: Molecular regulation of NLRP3 inflammasome activation during parasitic infection. Biosci. Rep. 44, BSR20231918 (2024). https://doi.org/10.1042/BSR20231918
33. Kawai, T., Autieri, M.V., Scalia, R.: Adipose tissue inflammation and metabolic dysfunction in obesity. Am. J. Physiol. - Cell Physiol. 320, C375–C391 (2021). https://doi.org/10.1152/ajpcell.00379.2020
34. Uti, D.E., Atangwho, I.J., Alum, E.U., Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
35. Cohen, L., Livney, Y.D., Assaraf, Y.G.: Targeted nanomedicine modalities for prostate cancer treatment. Drug Resist. Updat. 56, 100762 (2021). https://doi.org/10.1016/j.drup.2021.100762
36. He, Y., Wang, Y., Wang, L., Jiang, W., Wilhelm, S.: Understanding nanoparticle-liver interactions in nanomedicine. Expert Opin. Drug Deliv. 21, 829–843 (2024). https://doi.org/10.1080/17425247.2024.2375400
37. S, B., J, B., C, M., S, S., S, B., D, W., J, H., M, B., R, S.: Poly(Sarcosine) Surface Modification Imparts Stealth-Like Properties to Liposomes. Small Weinh. Bergstr. Ger. 15, (2019). https://doi.org/10.1002/smll.201904716
38. Strand, K., Stiglund, N., Haugstøyl, M.E., Kamyab, Z., Langhelle, V., Lawrence-Archer, L., Busch, C., Cornillet, M., Hjellestad, I.D., Nielsen, H.J., Njølstad, P.R., Mellgren, G., Björkström, N.K., Fernø, J.: Subtype-Specific Surface Proteins on Adipose Tissue Macrophages and Their Association to Obesity-Induced Insulin Resistance. Front. Endocrinol. 13, 856530 (2022). https://doi.org/10.3389/fendo.2022.856530
39. Du, J., Lane, L.A., Nie, S.: Stimuli-Responsive Nanoparticles for Targeting the Tumor Microenvironment. J. Control. Release Off. J. Control. Release Soc. 219, 205–214 (2015). https://doi.org/10.1016/j.jconrel.2015.08.050
40. Miao, Y.-B., Xu, T., Gong, Y., Chen, A., Zou, L., Jiang, T., Shi, Y.: Cracking the intestinal lymphatic system window utilizing oral delivery vehicles for precise therapy. J. Nanobiotechnology. 21, 263 (2023). https://doi.org/10.1186/s12951-023-01991-3
41. Matthew, S.A.L., Rezwan, R., Kaewchuchuen, J., Perrie, Y., Seib, F.P.: Mixing and flow-induced nanoprecipitation for morphology control of silk fibroin self-assembly. RSC Adv. 12, 7357–7373. https://doi.org/10.1039/d1ra07764c
42. Thiruvengadam, R., Kondapavuluri, B.K., Thangavelu, L., Thiruvengadam, M., Hatami, M., Kim, J.H.: Nanoparticle-based strategies with bioactive compounds for targeting oxidative stress in therapeutic interventions: A comprehensive review. Ind. Crops Prod. 227, 120804 (2025). https://doi.org/10.1016/j.indcrop.2025.120804
43. Aljabri, A., Soliman, G.M., Ramadan, Y.N., Medhat, M.A., Hetta, H.F.: Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems. Clin. Exp. Med. 25, 107 (2025). https://doi.org/10.1007/s10238-025-01558-6
44. Han, Y.-H., Lee, K., Saha, A., Han, J., Choi, H., Noh, M., Lee, Y.-H., Lee, M.-O.: Specialized Proresolving Mediators for Therapeutic Interventions Targeting Metabolic and Inflammatory Disorders. Biomol. Ther. 29, 455–464 (2021). https://doi.org/10.4062/biomolther.2021.094
45. Belgrad, J., Fakih, H.H., Khvorova, A.: Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation. Nucleic Acid Ther. 34, 52–72 (2024). https://doi.org/10.1089/nat.2023.0068
46. Aldosari, B.N., Alfagih, I.M., Almurshedi, A.S.: Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. Pharmaceutics. 13, 206 (2021). https://doi.org/10.3390/pharmaceutics13020206
47. Borges, A., de Freitas, V., Mateus, N., Fernandes, I., Oliveira, J.: Solid Lipid Nanoparticles as Carriers of Natural Phenolic Compounds. Antioxidants. 9, 998 (2020). https://doi.org/10.3390/antiox9100998
48. El Moukhtari, S.H., Garbayo, E., Amundarain, A., Pascual-Gil, S., Carrasco-León, A., Prosper, F., Agirre, X., Blanco-Prieto, M.J.: Lipid nanoparticles for siRNA delivery in cancer treatment. J. Control. Release Off. J. Control. Release Soc. 361, 130–146 (2023). https://doi.org/10.1016/j.jconrel.2023.07.054

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

49. Divella, R., De Luca, R., Abbate, I., Naglieri, E., Daniele, A.: Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J. Cancer. 7, 2346–2359 (2016). https://doi.org/10.7150/jca.16884
50. Makki, K., Froguel, P., Wolowczuk, I.: Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells, Cytokines, and Chemokines. Int. Sch. Res. Not. 2013, 139239 (2013). https://doi.org/10.1155/2013/139239
51. Shargh, Z., Asghari, K., Asghariehahari, M., Chodari, L.: Combined effect of exercise and curcumin on inflammation-associated microRNAs and cytokines in old male rats: A promising approach against inflammaging. Heliyon. 11, e41895 (2025). https://doi.org/10.1016/j.heliyon.2025.e41895
52. Gharavi, A.T., Hanjani, N.A., Movahed, E., Doroudian, M.: The role of macrophage subtypes and exosomes in immunomodulation. Cell. Mol. Biol. Lett. 27, 83 (2022). https://doi.org/10.1186/s11658-022-00384-y
53. Kou, M., Huang, L., Yang, J., Chiang, Z., Chen, S., Liu, J., Guo, L., Zhang, X., Zhou, X., Xu, X., Yan, X., Wang, Y., Zhang, J., Xu, A., Tse, H., Lian, Q.: Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool? Cell Death Dis. 13, 1–16 (2022). https://doi.org/10.1038/s41419-022-05034-x
54. AlQurashi, D.M., AlQurashi, T.F., Alam, R.I., Shaikh, S., Tarkistani, M.A.M.: Advanced Nanoparticles in Combating Antibiotic Resistance: Current Innovations and Future Directions. J. Nanotheranostics. 6, 9 (2025). https://doi.org/10.3390/jnt6020009
55. Beniwal, N., Verma, A., Putta, C.L., Rengan, A.K.: Recent Trends in Bio-nanomaterials and Non-invasive Combinatorial Approaches of Photothermal Therapy against Cancer. Nanotheranostics. 8, 219–238 (2024). https://doi.org/10.7150/ntno.91356
56. Fang, H., Cavaliere, A., Li, Z., Huang, Y., Marquez-Nostra, B.: Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer. Front. Pharmacol. 12, (2021). https://doi.org/10.3389/fphar.2021.627693
57. Kashyap, B.K., Singh, V.V., Solanki, M.K., Kumar, A., Ruokolainen, J., Kesari, K.K.: Smart Nanomaterials in Cancer Theranostics: Challenges and Opportunities. ACS Omega. 8, 14290–14320 (2023). https://doi.org/10.1021/acsomega.2c07840
58. La-Beck, N.M., Islam, Md.R., Markiewski, M.M.: Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine. Front. Immunol. 11, 603039 (2021). https://doi.org/10.3389/fimmu.2020.603039
59. Ray1, P., Haideri2, N., Haque2, I., Mohammed2, O., Chakraborty2, S., Banerjee2, S., 3#, Quadir1#, M., Brinker 4, A.E., 5, Banerjee2, and S.K., 3*: The Impact of Nanoparticles on the Immune System: A Gray Zone of Nanomedicine. J. Immunol. Sci. 5, (2021)
60. Salawu, A., Hernando-Calvo, A., Chen, R.Y., Araujo, D.V., Oliva, M., Liu, Z.A., Siu, L.L.: Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials. Eur. J. Cancer Oxf. Engl. 1990. 173, 167–177 (2022). https://doi.org/10.1016/j.ejca.2022.06.045
61. Abdelmalek, M.F., Suzuki, A., Sanchez, W., Lawitz, E., Filozof, C., Cho, H., Baek, E., Choi, J., Baek, S.: A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study. Contemp. Clin. Trials. 130, 107176 (2023). https://doi.org/10.1016/j.cct.2023.107176

CITE AS: Bwanbale Geoffrey David. (2026). Nanomedicine-Based Strategies to Target Chronic Inflammation in Obesity-Driven Type 2 Diabetes. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY,7(1):87-94.
https://doi.org/10.59298/NIJPP/2026/718794